Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

36.49
-0.0328-0.09%
Post-market: 36.490.00000.00%16:10 EDT
Volume:129
Turnover:5K
Market Cap:19.16M
PE:- -
High:36.49
Open:36.49
Low:36.49
Close:36.52
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.18
T/O Rate:0.02%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

GlobeNewswire
·
Sep 28

Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan

TIPRANKS
·
Sep 28

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

GlobeNewswire
·
Sep 28

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28

Lilly Launches Initiative to Expand Diabetes, Obesity Drug Access

MT Newswires Live
·
Sep 28

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

GlobeNewswire
·
Sep 28

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

GlobeNewswire
·
Sep 28

Eli Lilly launches ‘Lilly Change the Course Commitment’

TIPRANKS
·
Sep 28

Merck enters global license agreement with SciBrunch Therapeutics for SPR2015

TIPRANKS
·
Sep 28

Merck Enters into Exclusive Global License Agreement with Scibrunch Therapeutics for Spr2015, an Investigational Oral Kras G12d (On) Inhibitor

Reuters
·
Sep 28

Eli Lilly - to Register Diabetes and Obesity Medicines in Lmics and Expand Access

THOMSON REUTERS
·
Sep 28

Eli Lilly - Aims to Treat Equal Number of Patients in Lmics and High-Income Countries by 2040

THOMSON REUTERS
·
Sep 28

Merck & Co - to Record $400 Mln Pre-Tax Charge, $0.13 Per Share, in Q3 2026

THOMSON REUTERS
·
Sep 28

Merck & Co - Deal Includes $400 Mln Upfront, Total Potential Value $2.13 Bln; Deal Closed

THOMSON REUTERS
·
Sep 28

Merck & Co Inc: Under Agreement, Scibrunch Granted Co Exclusive Rights to Develop, Manufacture & Commercialize Spr2015 Worldwide

THOMSON REUTERS
·
Sep 28

MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001

TIPRANKS
·
Sep 28

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

TIPRANKS
·
Sep 28

JPMorgan Adjusts Price Target on Eli Lilly to $1,500 From $1,400, Maintains Overweight Rating

MT Newswires Live
·
Sep 28

Merck's Keytruda Subcutaneous Formulation Approved for Launch in China

Stock News
·
Sep 28

Ingenia Therapeutics Expects USD 5 Million MK-8748 Milestone Payment from Merck Unit Eyebiotech

Reuters
·
Sep 28